Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis c virus genotype 1 infection

Journal of Clinical Microbiology

Volumn 52, Issue 1, 2014, Pages 193-200

  Akuta, Norio ^a   Suzuki, Fumitaka ^a   Fukushima, Taito ^a   Kawamura, Yusuke ^a   Sezaki, Hitomi ^a   Suzuki, Yoshiyuki ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Hara, Tasuku ^a   Kobayashi, Mariko ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MP 424; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1 INFECTION; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; JAPANESE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; ULTRADEEP SEQUENCING; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; JAPAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891510786     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02371-13     Document Type: Article

References (29)

1. Lin C, Kwong AD, Perni RB. 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 6:3-16. http://dx.doi.org/10.2174/ 187152606776056706.
2. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360:1827-1838. http://dx.doi.org/10.1056/NEJMoa0806104.
3. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839-1850. http://dx.doi.org/10. 1056/NEJMoa0807650.
4. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. 2012. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J. Hepatol. 56:78-84. http://dx.doi.org/10.1016/j.jhep.2011.07.016.
5. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team. 2010. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362:1292-1303. http://dx.doi.org/10.1056/NEJMoa0908014.
6. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD. 2005. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280:36784-36791. http://dx.doi.org/10.1074/jbc. M506462200.
7. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631-639. http://dx.doi.org/10.1002/hep.21781.
8. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. 2013. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 57:221-229. http://dx.doi.org/10.1093/cid/cit226.
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401. http://dx.doi.org/10.1038/nature08309.
10. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41:1100-1104. http://dx.doi.org/10.1038/ng.447.
11. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genomewide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109. http://dx.doi.org/10.1038/ng.449.
12. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. 2001. A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet. 46:471-477. http://dx.doi.org/10.1007/s100380170047.
13. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K. 2003. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34:395-402. http://dx.doi.org/10.1038/ng1206.
14. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. U. S. A. 87:9524-9528. http://dx.doi.org/10.1073/pnas.87.24 .9524.
15. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and nonvirological response to interferon-ribavirin combination therapy. Intervirology 48:372-380. http://dx.doi.org/10.1159/000086064.
16. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:77-81. http://dx.doi.org/10.1056/ NEJM199601113340203.
17. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. 2008. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:38-47. http://dx.doi.org/10.1002/hep.22339.
18. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H. 2012. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J. Clin. Virol. 54: 352-354. http://dx.doi.org/10. 1016/j.jcv.2012.04.024.
19. Romano KP, Ali A, Royer WE, Schiffer CA. 2010. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. U. S. A. 107: 20986-20991. http://dx.doi.org/10.1073/pnas.1006370107.
20. Barbotte L, Ahmed-Belkacem A, Chevaliez S, Soulier A, Hézode C, Wajcman H, Bartels DJ, Zhou Y, Ardzinski A, Mani N, Rao BG, George S, Kwong A, Pawlotsky JM. 2010. Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease. Antimicrob. Agents Chemother. 54:2681-2683. http://dx.doi.org/10.1128/AAC .01796-09.
21. Elliott AM, Radecki J, Moghis B, Li X, Kammesheidt A. 2012. Rapid detection of the ACMG/ACOG-recommended 23 CFTR disease-causing mutations using ion torrent semiconductor sequencing. J. Biomol. Tech. 23:24-30. http://dx.doi.org/10.7171/jbt.12-2301-003.
22. Vogel U, Szczepanowski R, Claus H, Jünemann S, Prior K, Harmsen D. 2012. Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information. J. Clin. Microbiol. 50:1889-1894. http://dx.doi.org/10.1128/JCM. 00038-12.
23. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2013. Emergence of telaprevir-resistant variants detected by ultradeep sequencing after triple therapy in patients infected with HCV genotype 1. J. Med. Virol. 85:1028-1036. http://dx.doi.org/10.1002/jmv .23579.
24. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. 2010. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429. http://dx.doi.org/10.1002/hep.23690.
25. Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H. 2011. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis. 204:84-93. http://dx.doi.org/10.1093/infdis/jir210.
26. Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2013. Prediction of treatment efficacy and telaprevirresistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. J. Clin. Microbiol. 51:2862-2868. http://dx.doi.org/10.1128/JCM.01129-13.
27. Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K. 2011. Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo. Hepatology 54:781-788. http://dx.doi.org/10.1002/hep .24460.
28. Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, Sato T, Kamiya N, Yamada I, Chayama K, Kumada H, Toyota J. 2011. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J. Gastroenterol. 46:929-937. http://dx.doi.org/10.1007/s00535-011-0411-0.
29. Bartenschlager R, Lohmann V. 2000. Replication of hepatitis C virus. J. Gen. Virol. 81:1631-1648.